Table 1.
Participant Characteristics, Mean (SD)
| Age (years) | PD Duration (years) | MDSUPDRS Part 2 (ADL) | MDSUPDRS Part 3 (motor) | GDS | PDQ-39Stigma | LED (mg/day) | |
|---|---|---|---|---|---|---|---|
| Entire sample (N=362) | 67.0 (8.8) | 6.1 (4.7) | 12.7 (7.5) | 32.2 (14.6) | 7.3 (5.4) | 14.9 (17.6) | 652.0 (556.8) |
| Men (n=205) | 67.4 (8.9) | 6.3 (4.7) | 13.1 (7.8) | 34.2 (15.0) | 7.4 (5.3) | 14.5 (18.5) | 680.4 (531.5) |
| Women (n=157) | 66.5 (8.5) | 5.8 (4.6) | 12.3 (7.0) | 29.6 (13.8) | 7.2 (5.6) | 15.3 (16.4) | 614.9 (588.0) |
PD = Parkinson’s disease; MDS-UPDRS = Movement Disorders Society Unified Parkinson’s Disease Rating Scale; ADL = Activities of Daily Living; GDS = Geriatric Depression Scale; PDQ-39 = 39-item Parkinson’s Disease Questionnaire; LED = Levodopa equivalent dosage; SD = standard deviation; The sample size for all variables was 362 with the exception of the GDS (n=384; 198 men, 150 women) and LED (n=360; 204 men, 156 women). The numbers of participants categorized as tremor dominant, postural instability and gait difficulty, and indeterminate were 110, 223, and 29, respectively. MDS-UPDRS values reflect the onmedication state.